Blueprint Medicines Corporation
BPMC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $149 | $146 | $128 | $138 |
| % Growth | 2.1% | 14.2% | -7.2% | – |
| Cost of Goods Sold | $3 | $7 | $2 | $11 |
| Gross Profit | $147 | $139 | $126 | $127 |
| % Margin | 98.1% | 94.9% | 98.5% | 91.9% |
| R&D Expenses | $92 | $84 | $85 | $81 |
| G&A Expenses | $0 | $66 | $63 | $67 |
| SG&A Expenses | $96 | $96 | $90 | $89 |
| Sales & Mktg Exp. | $0 | $30 | $27 | $23 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $188 | $180 | $175 | $170 |
| Operating Income | -$41 | -$41 | -$49 | -$43 |
| % Margin | -27.5% | -28.2% | -38.2% | -31.2% |
| Other Income/Exp. Net | $42 | -$8 | -$7 | -$7 |
| Pre-Tax Income | $1 | -$49 | -$56 | -$50 |
| Tax Expense | $1 | $1 | $0 | $0 |
| Net Income | $0 | -$50 | -$56 | -$50 |
| % Margin | 0.3% | -34.1% | -43.9% | -36.2% |
| EPS | 0.01 | -0.79 | -0.89 | -0.8 |
| % Growth | 101.3% | 11.2% | -11.2% | – |
| EPS Diluted | 0.01 | -0.79 | -0.89 | -0.8 |
| Weighted Avg Shares Out | 64 | 64 | 63 | 63 |
| Weighted Avg Shares Out Dil | 64 | 64 | 63 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10 | $11 | $10 |
| Interest Expense | $8 | $18 | $19 | $17 |
| Depreciation & Amortization | -$34 | $4 | $4 | $4 |
| EBITDA | -$41 | -$27 | -$33 | -$29 |
| % Margin | -27.5% | -18.5% | -26% | -21.3% |